Scrip
Eisai to file first in-house anticancer in major markets for breast cancer
02 November 2009
Malini Guha
Eisai plans to file its new chemotherapy drug eribulin (E7389) – its first oncology drug developed in-house – for pre-treated locally advanced or metastatic breast cancer in Japan, the US and the EU by the end of its fiscal year ending March 2010 after it improved overall survival in patients who had...
Please Login to read the full article.
02 November 2009
Malini Guha
Please Login to read the full article.
RELATED CONTENT
NEWS
- Sustained release Aricept and eribulin key near-term R&D projects for Eisai
- US panel says toxicities of J&J's Yondelis outweigh benefits
- Avastin shows PFS benefit in third breast cancer trial but fails again to improve survival
- Genmab starts trial of Arzerra vs rituximab in non-Hodgkin's lymphoma
COMMENT
Other Informa Comment
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
